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Abstract 
The aim of cost-utility analysis is to support decision making in healthcare by providing a 
standardised mechanism for comparing resource use and health outcomes across 
programmes of work. The focus of this paper is the denominator of the cost-utility analysis, 
specifically the methodology and statistical challenges associated with calculating quality 
adjusted life years (QALYs) from patient level data collected as part of a trial. We provide a 
brief description of the most common questionnaire used to calculate patient level utility 
scores, the EQ-5D, followed by a discussion of other ways to calculate patient level utility 
scores alongside a trial including other generic measures of health-related quality of life and 
condition and population specific questionnaires. Detail is provided on how to calculate the 
mean QALYs per patient including discounting, adjusting for baseline differences in utility 
scores and a discussion of the implications of different methods for handling missing data. 
The methods are demonstrated using data from a trial. As the methods chosen can 
systematically change the results of the analysis it is important that standardised methods 
such as patient level analysis are adhered to as best as possible. Regardless researchers 
need to ensure that they are sufficiently transparent about the methods they use so as to 
provide the best possible information to aid in healthcare decision making.  
 
Key points for decision makers 
 It is best practice for analysts to be open and transparent about how utility scores are 
used to calculate quality adjusted life years (QALYs) for cost-utility analysis. This 
includes reporting the questionnaire used, the tariff or method applied to calculate 
utility scores and for which country, how the issue of missing data has been 
addressed and if the results have been adjusted for differences in baseline utility 
scores. 
 QALYs should be calculated as area under the curve, discounting for time horizons 
longer than a year and adjusting for baseline differences using regression analysis. 
Calculating QALYs using individual level data is more methodologically rigorous than 
calculating group means at different time points.  
 Multiple imputation is considered the most appropriate way to handle missing data. 
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1. Introduction 
The aim of cost-utility analysis is to aid in decision analysis in health care. In particular, it 
provides a standardised mechanism for comparing resource use and health outcomes 
across health care technologies and disease areas. The term was coined to differentiate it 
from cost-effectiveness analysis: a health economic evaluation where the denominator of the 
incremental cost-effectiveness ratio (ICER) is a cost per unit change in a disease or 
programme specific outcome, for instance cost per depression free day or cost per infection 
prevented. Instead, the outcome in the denominator of the cost-utility analysis ICER is a 
compound measure of mortality and morbidity quantified using preferences or risk in a 
standardised way [1]. The quantity and quality of life is then combined to calculate quality-
adjusted life years (QALYs), disability-adjusted life years (DALYs) or a variant thereof. As 
the units of analysis are standardised they theoretically make it easier to compare the health 
and social care resource implications of different programmes and disease areas. Also to 
note is that cost-utility analysis is still called cost-effectiveness analysis in the US and in the 
UK a cost-utility analysis may be referred to as a cost-effectiveness analysis or cost-utility 
analysis depending on the author’s preference [1].  
In health technology assessments in developed countries QALYs are the most commonly 
used outcome in the denominator of the cost-utility analysis. QALYs are calculated by 
weighting each year of life lived using a utility score.  Utility scores are anchored so that 1 is 
perfect health and 0 is equivalent to the state of death. In some models negative scores are 
possible, representing states that are theoretically worse than death. Multiplying time in a 
health state by the health state utility value, one year of life lived in perfect health is equal to 
1 QALY. If a person were to live for 2 years in a health state that is weighted as 0.5 of full 
health this is also equivalent to 1 QALY. The utility value and hence QALYs are valued 
independently of a person’s age, so 1 QALY is the same for someone who is 18 years of 
age as for someone who is 80 years of age [2]. 
The term “utility” in cost-utility analysis and its theory is based on von Neumann-Morgenstern 
(vN-M) utility theory. The normative model for utility theory, the model for how a rational 
individual ought to behave, is that utility scores represent the strength of an individual’s 
preference when faced with uncertainty for a given outcome, in this case a health state. 
There is a number of conditions that utility scores should meet, and although the model is 
normative, it should somewhat reflect the way individuals make decisions when faced with 
uncertainty (some empirical research however suggests these conditions may be more often 
violated than met [2]). VN-M utility theory also assumes that utility scores are cardinal in that 
individuals are able to quantify the extent to which they prefer one health state to another. 
This is as opposed to scores being purely ordinal; individuals are only able to order health 
states in terms of preference. Theoretically, utility scores that form the basis of QALYs are 
meant to have these qualities, making them as close as possible to the utility scores in vN-M 
utility theory [1]. The area though is not without its controversies and the terminology used 
can be confusing.  “Utility” in vN-M utility theory and in the calculation of QALYs should not 
be confused with the way that the word utility is used in other areas of economics such as 
welfare theory and Pareto optimisation [2].  
Although the original purpose of cost-utility analysis was to aid in decision making related to 
the allocation of scarce health care resources, the utility scores used to calculate QALYs 
have found their way into more general analyses of health and social care programmes, with 
statisticians and economists alike using them to draw conclusions about the effectiveness of 
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health and social care interventions, policies and technologies. Nevertheless, there is a 
range of methods that analysts can use to calculate QALYs and account for missing data. A 
literature review by Richardson and Manca [3] identified a number of different ways way that 
QALYs were calculated in cost-utility analyses alongside randomised control trials. They 
identified that the calculation of QALYs in many cases lacked consistency and that there was 
poor reporting of methods. Reporting of missing data and how it was handled were of 
particular concern, with almost a half of papers not reporting the amount of missing data and 
only one fifth with missing data including and describing a method of data imputation. The 
authors recommend that cost-utility analyses need to be fully transparent with consistent 
analytical techniques employed, as different methods can influence the direction and 
significance of the results [3].  As utility scores gain increasing appeal with a wider range of 
analytical disciplines the risk of miscommunication and misinterpretation of analyses of utility 
scores increases. 
The focus of this article is the denominator of the cost-utility analysis, specifically the 
calculation of QALYs in the incremental cost per QALY gained analysis. We aim to re-
orientate utility scores towards their original standardised purpose and provide guidance to 
analysts including statisticians, epidemiologists and junior health economists, new to 
economic evaluation on how to calculate QALYs from utility scores collected as part of a 
trial, highlighting specific statistical issues that are important to address. We firstly provide a 
brief description of the most common questionnaire used to calculate patient level utility 
scores, the EQ-5D, followed by a discussion of other ways to calculate patient level utility 
scores alongside a trial including other generic measures of health-related quality of life and 
condition and population specific questionnaires. In section five we go into detail on how to 
calculate the mean QALYs per patient using patient data that has been collected as part of a 
trial. Building on the formulas set out in section five we describe the methods for discounting 
and adjusting for baseline differences. In the final two sections we describe different ways to 
handle missing data including multiple imputation in section eight.  
2. Utilities from the EQ-5D 
Calculating patient level utility scores as part of a trial is usually made up of two steps: (1) 
asking patients to complete a generic measure of health-related quality of life at different 
time points over the duration of the trial, including baseline to measure a patient’s health 
status; and (2) applying a preference based algorithm to calculate utility scores for each 
patient’s health status at each time point.  
The key body responsible for providing advice and guidance on best clinical practice 
including value for money in England (the National Institute for Health and Care Excellence, 
NICE) recommends that utility scores are obtained from a random sample of the general 
population and using a technique called time trade-off (TTO) to arrive at a measure of 
preference under uncertainty for a given health state [4].  The generic questionnaire most 
favoured in the UK is the EuroQol group’s EQ-5D and the variant currently most commonly 
used is the 3 level version. This questionnaire consists of five questions asking if patients 
have no, some or extreme problems with mobility, self-care, usual activities, pain and 
anxiety/depression. In total the questionnaire defines 243 distinct health states, each of 
which have an associated, country specific, utility score representing the preferences of a 
sample of the general population of that country. In the UK the utility scores for the EQ-5D 3 
level ranges from 1 for perfect health to -0.594 - states worse than death are possible with 
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this value set, which are given negative scores [6]. A 5 level version of the EQ-5D is 
available and preference based health state valuations from a random sample of the general 
population are in the process of being derived [7].  
It should be noted that the issues discussed in this paper are not specific to utility scores 
derived from the EQ-5D but also to other generic measures of health-related of quality life 
and condition and population specific measures that have preference based algorithms and 
can be used to calculate utility scores for health states. The other methods will be discussed 
in the next two sections. If the method used is something other than using a country specific 
version of the EQ-5D to calculate QALYs, caution should be exercised when comparing the 
results of this analysis with others as the results will systematically vary from method to 
method [8]. 
3. Calculating utility scores using other generic measures 
In some instances the view is taken that the EQ-5D is not suitable for a particular patient 
group or disease [9]. It is also the case that in some trials EQ-5D data is not collected. Data 
from other generic measures of health-related quality of life might have been collected 
though. Brazier et al. [10] developed a 6 dimension classification of another measure of 
generic health-related quality of life that is commonly used in trials: the short form 36 and 
short form 12 (SF-36 and SF-12). The 6 dimension classification system, commonly referred 
to as the SF-6D, then has utility values from members of the general public using the 
standard gamble and an algorithm to convert either the SF-36 or SF-12 into a single utility 
score. Another example includes the multi attribute health status classification system: 
Health Utilities Index (HUI). The HUI has associated utility scores derived from a Canadian 
population [11]. The HUI2, which is designed to be used in children, has a UK algorithm for 
calculating utility scores [12].  Another generic health-related quality of life questionnaire for 
use in children with an associated UK preference set is the Child Health Utility 9D (CHU 9D) 
[13]. 
4. Calculating utility scores using condition specific measures and mapping.  
In addition, criticism has been levelled at some of the measures as they do not capture 
domains of interest, for example there are no questions in the EQ-5D directly relating to 
vision, fatigue or cognition [9]. To attempt to address this issue new utility preference sets 
based on TTO or SG have been generated from a condition specific questionnaire. This 
includes in cancer, where a specific utility value set has been generated for the commonly 
used EORTC-QLQ-C30 [14] and in epilepsy where a utility value set has been developed for 
the NEWQOL-6D questionnaire for epilepsy [15]. Questionnaires and utility value sets have 
also been generated for specific populations that might struggle to fill in the traditional 
questionnaires or where extra domains where considered suitable. For example, to address 
the challenges of QoL measurement for patients with dementia the DEMQoL [16] and its 
associated value sets [17] have been developed. It is recommended that these 
questionnaires are used alongside the EQ-5D for consistency, and as it is currently unclear 
what impact that might have on utility estimates [17]. Another issue, particularly pertinent to 
patients where cognitive ability is limited or they are too unwell to complete the 
questionnaire, is completion of questionnaires by proxies compared to self-completion. The 
EQ-5D has a proxy completed version, although the validation of this has been limited and 
the viewpoint of the proxy is an important determinant of how the questionnaire is completed 
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and the resulting utility scores [18]. Researchers concerned about consistency are advised 
to use both proxy and patient completion where possible [17]. This is not always possible 
though and in these instances the person completing the questionnaire should be noted 
(individual or proxy) and a sensitivity analysis conducted.   
Another solution for calculating utility scores when EQ-5D data has not been collected is to 
use a mapping algorithm derived from “mapping” a generic preference based measure of 
health-related quality of life onto a condition specific questionnaire. Commonly used 
condition specific measures with a mapping algorithm are the European Organization for 
Research and Treatment of Cancer Core Quality of Life Questionnaire EORTC-30 in cancer 
[19] and the Barthel index in stroke care [20]. Extreme caution needs to be exercised when 
using mapping algorithms though as in many cases they can over or under predict 
significantly for some patients, partially because of the methods used to derive the 
algorithms [21]. 
A more thorough discussion of the issues of using a condition specific instrument for 
calculating utility scores can be found in Brazier et al [22]. 
 
5. Calculating a QALY 
The following sections use trial data to illustrate how to calculate QALYs and the impact that 
different methods and assumptions can have on the direction and magnitude of the results of 
an analysis. Following the collection of patient health status as part of the trial, and once the 
algorithm for that measure is applied to calculate utility scores for patients, the most 
commonly accepted way to calculate QALYs is to calculate the area under the curve (AUC) 
joining the utility measurements at each point in time [1]. To illustrate the calculation of 
QALYs we use trial data from real patients with data on follow-up time points of 6 months, 1 
year and 2 years for 152 patients (85 in the treatment group and 67 in the control group) 
[23]1.  The treatment arm involved a health check at baseline for patients with intellectual 
disabilities; the control group received usual care.  Figure 1 and columns 2 and 3 of table 1 
show mean utility scores calculated from the EQ-5D over the two year period for the 
treatment and control groups and the numbers with complete EQ-5D value sets in table 2. 
The amount of missing data for the EQ-5D at each follow-up point is reported in table 2.  
There are two broad ways that the AUC can be calculated: (i) at the patient level using 
patient level data at each follow-up point; (ii) at the group level using the mean utility score 
for each follow-up point.  
The recommended method is to calculate QALYs using individuals’ utility scores at different 
time points. 
𝑞𝑗𝑡𝑖 =
(𝑢𝑗(𝑡−1)𝑖 + 𝑢𝑗𝑡𝑖)
2
𝛿𝑡 
(1) 
                                                          
1
 Original follow-up points for trial data were 3, 6 and 9 months. These have been extended so as to 
demonstrate the impact of discounting which only occurs after 1 year. 
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The formula to calculate the AUC or QALYs using patient level data  is shown above in 
Formula 1, where u is the utility score, i denotes an individual, and j is time so that at 
baseline t=0. For each group j (j=0 for control and j=1 for treatment) the consecutive time 
measures are added, averaged and then re-scaled (δ) for the percentage of a year that t and 
t - 1 cover, so 0.5 for 6 months or 0.25 for 3 months and so on.  
𝑄𝑗𝑖 = ∑ 𝑞𝑗𝑡𝑖
𝑇
𝑡=1
 
(2) 
𝑄𝑗 =
∑ 𝑄𝑗𝑖
𝑛
𝑖=1
𝑛
 
(3) 
For the total duration of the trial, the total QALYs (Q) for each individual are the summation 
of the QALY calculations for each follow up time point starting at t=1, the first follow up point 
(formula 2). The mean QALYs for each treatment group (Qj) are then calculated from the 
individual level data, dividing the sum of all QALYs for all patients (∑ 𝑄𝑗𝑖) by the number of 
patients, (𝑛) (formula 3). Standard deviations, standard errors and confidence intervals can 
then be calculated using standard formulas from the individual level data in formula 2.  Most 
statistical packages will omit individuals with any missing data on the questionnaire or utility 
score at any time point from the analysis if no adjustment to the analysis is made to account 
for this. Hence the resulting analysis will be an individual level, complete case analysis (only 
individuals who have utility scores at baseline and all follow up time points will be included). 
In the example data set at the final follow-up point, 24 months, 85% of participants have 
complete responses to the EQ-5D in the control group and 83% in the treatment group. 
Across all time points though, only 70% of participants in the control group and 71% of 
participants in the treatment group have complete responses to the EQ-5D (see table 2).   
When an individual level, complete case analysis is run using the example data set the total 
mean QALYs for the control group are 1.47 (95% CI 1.36-1.57) and for the treatment group 
are 1.39 (95% CI 1.27-1.51) (see table 3). 
When reporting the results of the analysis the mean utility score and standard deviations for 
each follow-up point might be reported to provide more detailed information. If this is done 
then care needs to be taken in reporting and interpreting these results. The mean utility for 
each treatment group (ujt), using all individuals with complete data at each time point, an 
available case analysis, was calculated using the example data set and is reported in Table 
1. If these available case means  are used to calculate the area under the curve adjusting for 
timing (𝛿) (formula 4) then summed for the total duration of the trial (formula 5) the results 
differ from the individual level analysis as additional individuals are included in the analysis. 
The total QALYs are 1.37 for the control group and 1.35 for the treatment group. A complete 
breakdown of the mean utility scores at each follow-up point and total mean QALYs as an 
available case analysis is reported in table 1 for illustration purposes.  
𝑞𝑗𝑡 =
(?̅?𝑗(𝑡−1) + ?̅?𝑗𝑡)
2
𝛿𝑡 
8 
 
(4) 
 
𝑄𝑗 = ∑ 𝑞𝑗𝑡
𝑇
𝑡=1
 
(5) 
 
Note that the results are different for the individual level complete case analysis compared to 
the available case analysis. If a complete case analysis is conducted using mean follow-up 
scores at the group level, so only including individual with complete questionnaires at all 
points, the results are the same as at the individual level (see table 3). It is important to note 
that both of these examples are for illustrative purposes only, so as to provide a description 
of the calculation of QALYs. Neither complete case analysis nor available case analysis 
adequately addresses the issue of missing data and hence both of them are biased. This will 
be discussed further in section 8 below. 
Both of these analyses also assume that the line drawn between utility scores and hence 
QALYs are linear. This significantly simplifies the analysis as the assumption of linearity 
allows two consecutive utility scores to be averaged, and then multiplied by the duration 
between the two scores. Some authors though have experimented with non-linear changes 
between consecutive time points (e.g. Miyatmoto [24]). These models are considerably more 
complex and, although they will report different results to a linear model, will only make a 
minimal difference to the results over short trial durations or if follow-up time points are 
close. Authors such as Billingham et al [25] have also investigated assumptions regarding 
changes over time and mortality using survival analysis provided recommendations for 
calculating QALYs.  
The SF-36 was also administered to patients in the example trial at baseline and the last 
follow up point, 2 years. Applying the SF-6D algorithm developed by Brazier et al [10] and 
doing a complete case analysis the mean QALYs for the control group are 1.51 (95% CI 
1.45 to 1.57) and for the treatment group 1.54 (95% CI 1.48 to 1.60).  
Note that the final score for the SF-36 and associated SF-6D algorithm is higher than that of 
the EQ-5D. This is common for studies using the SF-6D, partially because the range of utility 
scores for the two algorithms are not the same. Whereas the range of possibility utility 
values for the EQ-5D ranges from 1 to -0.594, with a number of health states that have utility 
scores worse than death, scores on the SF-6D are anchored at 1 for perfect health but with 
a minimum score of 0.316. As a result the SF-6D tends to be worse at discriminating 
between responses for patients in worse states of health. At the upper ranges though it 
tends to discriminate better, having less of a ceiling effect than the EQ-5D [26]. If using the 
SF-6D rather than the EQ-5D for an analysis one must be careful of this systematic bias 
when interpreting the results of the incremental cost effectiveness ratio.    
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6. Discounting 
In a cost-utility analysis both costs and QALYs need to be adjusted for the different times 
that they occur. Discounting is the process of accounting for time preferences in the receipt 
of costs or benefits. The standard discount rate used by NICE for both costs and benefits is 
3.5% [4], with a standard of 3% being consistent across other developed countries including 
the US [27]. For public health interventions NICE recommends a discount rate for costs and 
benefits of 1.5% [28]. Discounting can be done using group means or using individual level 
data, although it is recommended that discounting is done at the individual level, particularly 
due to issues associated with missing data, as will be discussed in section 8.  
𝑢𝑗𝑡𝑖 =  
𝑢𝑗𝑡𝑖
(1 + 𝑟)(𝑡−1)
 
(6) 
Formula 6 is the discount formula for calculating QALYs at an individual level using the utility 
score (u) for individual i at time t for a discount rate of r.  The discount rate is generally only 
applicable in cases where the duration of the trial is greater than 12 months. In this formula t 
is the time from baseline in years. It is possible though to do a monthly discount rate by 
converting the yearly discount rate r to a monthly value (Formula 7). The same discount rate 
formula still applies, but instead using the new 1 month rate and t becomes the time from 
baseline in months. In the case of a discount rate of 3.5%, 0.3% would be the monthly 
discount rate using Formula 7 below. 
𝑟𝑚𝑜𝑛𝑡ℎ = (1 + 𝑟)
1
12−1 
(7) 
Discounting has been applied to the example data set at the group level (available case 
analysis) to provide a worked example (see table 1). When applied at the individual level 
(complete case analysis) the new mean QALYs and 95% CI are 1.44 (95% CI 1.34-1.54) 
and 1.37 (95% CI 1.25-1.48). 
7. Adjusting for baseline differences 
In trials random allocation to the treatment or control group is the most common mechanism 
used to try to ensure balanced characteristics between treatment and control groups. 
Randomisation though is not a perfect mechanism for this and sometimes differences can 
occur between groups for patient characteristics that might have a significant impact on the 
results of the trial. For example, by chance, individuals in the control group may have more 
severe disease symptoms at baseline than individuals in the treatment group. Hence, other 
additional methods are sometimes used to try to minimise the impact that differences 
between groups can have on the results of the analysis, some of which can occur prior to 
randomisation, such as stratification. Stratification is where patients are randomised to 
intervention groups in such a way as to try to reduce significant differences between groups 
for a specific important characteristic, such as co-morbidities or symptom severity. 
Stratification can also be used in very specific situations, such as controlling for the random 
allocation to treatment groups between countries in a multi-country trial. 
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Another common technique, particularly in observational data, is adjusting for baseline 
characteristics where there is strong reason to believe that they could influence the outcome 
of interest. Adjusting for baseline differences in groups does come with caveats. Generally 
including variables used for stratification as covariates in a regression analysis is considered 
acceptable, and in some instances baseline variables that are known a prior to be strongly or 
moderately associated with the dependent variable in the analysis. However, it is important 
to note that variables that were measured after randomisation or that could be influenced 
post hoc by the treatment in any way should not be included as covariates for the purposes 
of baseline adjustment and the variables chosen should also be specified in the analysis 
plan [29].   
In the calculation of QALYs imbalances in baseline values has a different implication for the 
analysis. QoL is not a variable that is included in stratification and is generally a dependent 
variable, not a covariate in an analysis, so it is not intuitively adjusted for. It is possible 
though that the treatment or control group may differ in QoL or utility scores at baseline. The 
nature of calculating QALYs as AUC then means that one group may have more QALYs by 
virtue of their baseline utility scores alone, particularly if the treatment only has a minimal 
effect on QoL. In the example data set, by chance, the utility score for the control group is 
higher than for the treatment group, 0.68 (95% CI 0.61-0.74) versus 0.63 (0.57-0.70) 
respectively, although not significantly higher.   
There are a number of methods that can be used to adjust for baseline utility score 
differences, with linear regression with baseline adjustment being the recommended method 
[29].  
One approach that has commonly been used, and is the most intuitive, is to calculate the 
difference in utility score from baseline, so that only the actual change in utilities is computed 
and baseline differences are removed. Looking at the group means in table 1 only, in the 
control group there is an increase of 0.04 from baseline over the 2 years and for the 
treatment group an increase of 0.17. Using the individual level data in the example data set, 
the mean difference in utility score from baseline for the control group is -0.02 (95% CI -0.8 
to 0.4) and for the treatment group 0.16 (95% CI 0.09 to 0.23), with the increase in utility 
score being significantly different in the treatment compared to control group.  This 
methodology though presents significant problems for calculating QALYs for hypothesis 
testing as only the less informative mean difference from baseline is calculated. This method 
has also been criticised in the literature as it fails to control for imbalances due to regression 
to the mean; patients’ future scores are generally correlated with their past scores [30]. 
Instead the method that has been recommended is to use linear regression with baseline 
adjustment. In this instance QALYs for each individual are calculated as described in section 
5 above. A linear regression analysis is then run where the dependent variable is the total 
QALYs, β1 is the coefficient for the treatment effect and β2 the coefficient for baseline utility 
scores:  
𝑄𝑖 =  𝛽0 +  𝛽1(𝑗𝑖) + 𝛽2(𝑢𝑖,𝑡=0) 
(8) 
In this linear regression analysis the coefficient for β1 is then the difference in QALYs 
between treatment and control. In a standard statistics package like Stata this can be done 
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by running the regression analysis (regress total QALYs 
treatment_dummy_variable baseline_utility). Running this analysis on the 
example dataset the treatment co-efficient, β1, is 0.029 (95% CI -0.067 to 1.262). The mean, 
adjusted QALYs for each treatment group can also be calculated using most standard 
statistical packages. In Stata this is done by using the command adjust after running the 
regression analysis, and adjusting for baseline utility scores at mean (margins 
treatment_group, at(baseline_ utility=mean)). If this is done in the example 
dataset the mean patient level QALYs for the control group are 1.35 (95% CI 1.28 to 1.43) 
and for the treatment group they are 1.38 (95% CI 1.32 to 1.45) undiscounted. Including 
discounting they are 1.33 ( 95% CI 1.26 to 1.40) and 1.36 (95% CI 1.3 to 1.42) (see table 3). 
Note that this method only adjusts for baseline utility scores and not other baseline 
characteristics, which as mentioned above, is to be done with caution unless they are 
stratified variables or they are pre specified in the analysis plan.  
In this example, although adjusting for baseline differences does not change the conclusion 
(there is a non-significant difference between treatment and controls even after adjusting for 
baseline differences) it does change the direction of the difference from negative to positive.   
Although this does not change the conclusion of the analysis, there is no difference in QoL 
between the two groups, it may have an impact on the results of a cost-utility analysis once 
costs are added in. This is discussed further in section 9. 
Other statistical methods of varying levels of sophistication, particularly those that are 
designed to account for a range of baseline patient characteristics, are also possible. An 
example would be to fit a multi-level model with fixed and random effects. One option, which 
is explained more fully in Carpenter and Kenward [31], is to account for the repeated 
measures of utility within a patient as the response variable and include a random effect 
accounting for baseline response at the patient level.  This approach has the statistical 
advantage of parameterising the baseline measurement (eg accounting for measurement 
error on that value) and enabling analysis of data that are incomplete (eg subjects with say, 
only endpoint values, may be included). Fitting this multi-level model assuming a fixed effect 
for the treatment coefficient, the estimated mean undiscounted QALYs for the control group 
is 1.55 (95% CI 1.47 to 1.62) with an estimated reduction of QALYs for the treatment group 
of -0.0029 (95% CI -0.11 to 0.11). 
8. Missing data 
Missing data is a well-documented problem in health care data sets and methods to address 
it will almost always need to be considered within the statistical and economic evaluation 
analysis plan for any repeated measures patient level data set. In the first instance though it 
can be considered a trial design issue, where by trialists and research staff should ensure 
that the methods and resources they use to recruit and retain patients try to minimise the risk 
of missing data as best possible. In terms of costs for economic evaluations this can be 
addressed by taking data from medical records. For questionnaires that are not routine 
though this presents more of a challenge. Length of the questionnaire has been shown to 
have a negative correlation with probability of responding so shorter and fewer 
questionnaires are preferrable [32]. In this way the EQ-5D can be a good questionnaire 
given its relatively short length.  
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Once the data have been obtained, and the level of missingness ascertained, it is up to the 
analysts to handle the missing data appropriately. This would include an assessment of the 
mechanism of missingness: Is the data missing completely at random (MCAR)? This is 
where there is no relationship between the data that is missing and any values in the data 
set, missing or observed. Is the data missing at random (MAR)? This is where the 
missingness is not related to the missing data but an observed variable in the dataset. Or the 
missing data can be missing not at random (MNAR) where the propensity for data to be 
missing is related to the missing data. When data are MAR observed data can be used to 
estimate the results. There are different ways to test for which observed variable predicts if 
data are MAR, which are covered more fully in Little and Rubin [33], but once the 
mechanism for missingness is ascertained the most appropriate method for handling missing 
data needs to be chosen, taking into account the data available.  It should be noted though 
that there is no way to test if data are MCAR given that there is chance that the propensity 
for data to be missing is as a result of some individual characteristic that is missing from the 
data set. 
A recent systematic review of economic evaluations along randomised control trials (RCTs) 
found that missing data was rarely handled appropriately and in a fifth of cases it was 
unclear if it had been accounted for or was not mentioned at all. In a third of cases complete 
case analysis was the analysis method chosen [34]. Complete case analysis though is 
considered a poor statistical technique for dealing with missing data as it significantly biases 
the results. It makes the assumption that individuals whose data is missing within a data set 
have the same characteristics as those with complete data; that the data is missing 
completely at random. In most clinical trials this is unlikely to be the case. The most common 
bias is that individuals whose disease is more severe or who do not respond as well to 
treatment are more likely to have missing data, as they may be more unwell or have lost 
interest in the trial given it has provided them with no benefit. Individuals who fail to comply 
with treatment are also less likely to show up for further assessments and hence are more 
likely to have missing data.   
The level of missingness in the example data set at each follow up time point is reported in 
table 2. At 24 months 57 individuals have complete data in the control group and 71 in the 
treatment group. This represents approximately 85% of the participants in both groups. The 
main analysis used thus far has been a complete case analysis. Only 47 individuals in the 
control group and 60 in the treatment have complete data over the full duration of the trial, 
representing 70% of participants. To determine if there is an observable mechanism by 
which data are missing comparisons can be made between fully observed baseline 
characteristics, such as age, gender and intellectual ability, and the missing outcome, utility 
scores. One can then define a variable R, where R=1 if utility scores are observed at all 
follow-up points for an individual, or R=0 if there are any missing observations. It is then 
possible to test for differences in the rate of missingness (R) for fully observed baseline 
variables using simple statistical tests such as Chi-Square for categorical observed variables 
and T-tests for continuous. Although no relationship in the example data set was found 
between level of learning disability (mild, moderate, severe or profound) and missingness or 
gender and missingness, age was significantly related to the amount of missing data, with  
the older the individual the more likely they had missing data. EQ-5D utility scores at 
baseline were also significantly lower for individuals with missing data. In this instance one 
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can hypothesise that data is not missing at random, but that older individuals with lower 
quality of life are less likely to return subsequent questionnaires. 
There are a number of ways that one can work with missing data, although only three will be 
dealt with here; (i) taking the last utility value forward; (ii) taking the last questionnaire value 
forward; and (iii) multiple imputation (MI). These particular methods have been chosen 
because they illustrate two types of missing data analysis (simple and random) and the 
impact different methods can have on the outcome of the analysis. Taking the last value 
forward, examples i and ii, can be considered a simple approach to missing data. Another 
simple approach to missing data, that will not be addressed here, is imputing mean values. 
This particular option has not been chosen as from the previous analysis above it is clear 
that individuals with missing values vary systematically to those who do not, specifically 
having lower baseline utility values. Imputing mean results for follow up scores would bias 
the results of the analysis as it would potentially artificially inflate the follow-up utility scores. 
There are more ways to deal with missing data than the examples given.  A more complete 
review of the literature is available in Eekhout et al [35]. As a general rule though MI is the 
most appropriate technique to use when analysing patient level datasets with missing data. 
A more complete tutorial on MI methods is also available in White et al [36].    
8.1 Last value forward: utility score 
An assumption one might make when calculating the AUC is that the quality of life (QoL) or 
utility score of patients with missing data at point t is the same utility score they experienced 
in the previous time point (t-1). This essentially draws a straight, horizontal line from the last 
point with available data to the next point where data is available to calculate the area under 
the curve. It does introduce bias though in that if the reason individuals that were unable to 
complete questionnaires are because their health deteriorated and were too unwell to reply 
the values for these individuals will be artificially inflated. 
If this assumption is applied to the example data set then the mean QALYs for each group 
using a patient level analysis (formula 5)) the mean unadjusted, undiscounted QALYs  are 
1.35 (95% CI 1.22 to 1.46) for the control group and 1.35 (95% CI 1.25 to 1.46) for the 
treatment group; including discounting  and adjusting for baseline values (formula (8)) the 
mean QALYs are 1.3 (95% CI 1.22 to1.37) for the control group and 1.35 (95% CI 1.28 
to1.42) for the treatment group. 
8.2 Last value forward: questionnaire response 
In some instances utility scores cannot be calculated because not all items of the 
questionnaire are completed, rather than the whole questionnaire being missing; this is 
sometimes referred to “item-non response” (as opposed to unit- non response, where the 
whole questionnaire is missing). In the example data set, one item missing from the 
questionnaire accounted for a significant proportion of the missing utility scores at 6 and 24 
month follow ups. Similar to the previous method, the last value given for that question in the 
previous time-point can be assumed to be the same in this instance and EQ-5D scores 
calculated from there.  
If this assumption is applied to the example data set then the mean QALYs for each group 
using a patient level analysis (formula 5)) the mean unadjusted, undiscounted QALYs  are 
1.34 (95% CI 1.23 to 1.46) for the control group and 1.35 (95% CI 1.25 to 1.46) for the 
treatment group; including discounting  and adjusting for baseline values (formula (8)) the 
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mean QALYs are 1.3 (95% CI 1.22 to 1.37) for the control group and 1.35 (95% CI 1.28 to 
1.42) for the treatment group. 
The values are very similar to those where utility is replaced. As a result one can argue that 
it doesn’t matter whether you replace missing utility score or questionnaire values. On the 
other hand, the main underlying assumption behind this strategy is that given the past 
history, missingness is completely non informative. Thus, it is reasonable to assume that 
patients will continue to show the same behaviour as they have in the past. In most cases, 
this seems too stringent an assumption, thus potentially limiting the usefulness of these 
methods. In this instance given that the patients with the lowest utility are those that are the 
most likely to have missing values, using either of the last value forward methodologies does 
nothing to address the systematic bias associated with the missingness of the data.  In any 
case, it should be pointed out that the results are strongly dependent on this assumptions 
and thus extensive sensitivity analysis is recommended. 
8.3 Multiple Imputation  
One method that usually overcomes the severe limitations of last value forward and other 
simple imputation methods is that of stochastic multiple imputation. The basic idea is to 
“impute” the values that have not been observed with some summary obtained using the 
available data. Typically, this is done by taking random draws from a suitable probability 
distribution to account for the underlying uncertainty in the summary statistic. This random 
draw is used to represent the potential observation that just happens not to be available. A 
distinct characteristic of analyses based on multiple imputation is that rather than having a 
singular dataset where missing values are replaced by a new value, as is the case with 
simple imputation methods, for multiple imputation the original dataset remains as is, along 
with the missing values, and a number of new datasets are created where a new value is 
inserted in place of the missing one. In each new dataset the new imputed value varies 
between datasets, within likely ranges for the parameter and can be based on pre specified 
relationships with observed baseline characteristics, as will be described below. In summary, 
a number of new hypothetical datasets are created with different values imputed for the 
missing data, leaving the original dataset intact. The same analyses as previous are then run 
on the new datasets, which are combined using appropriate methods, to obtain an estimate 
of the parameter of interest, the standard error and the standard deviation.  
The selected probability model describes the joint variation of observed and unobserved 
values. One simple way of doing so is to set up a regression model (on a suitable scale), in 
which the variable for which missing data are present depends on some fully observed 
covariates. A by-product of this procedure is that it automatically takes into account the 
patient characteristics that are a) available to the researcher; and b) considered to be 
predictive of the missing mechanism. Of course, from the computational point of view, this 
implies that the analysis is generally more complex and requires more advanced statistical 
tools.  
To choose the number of imputed datasets to create, a general rule of thumb is to create m 
imputed datasets such that m is equal to the number of percentage points of missing data for 
the dependent variable [36]. In the example data set, across all time points a utility score 
was missing for 30% of data points, and hence 30 imputed datasets were created. 
Previously, when less computing power was available to run analyses it was generally 
recommended that three to ten datasets were created, with limited extra benefit obtained 
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after ten [33].  Given the additional computing power available today to run analyses even 
generating hundreds of imputed datasets will have little impact on the time taken to run 
analyses on relatively small trial datasets. To test though that an adequate number of 
datasets have been generated White et al [36] suggested the following additional tests: 
1) That the Monte Carlo error of the regression coefficient for the treatment variable, β1 
in formula 8, is approximately 10% of its standard error. 
2) The Monte Carlo error of the test statistic for β1, is approximately 0.1. 
They set a third assertion for the P-value given that the assumption is that p should be less 
than 0.05. Given that trials are rarely powered to find a difference in QALYs between 
treatment and control groups it is unlikely that there will be a difference between the two 
groups and hence this condition is rarely relevant for QALYs. The Monte Carlo estimate can 
be calculated in Stata using the command mcerr following the command mi estimate. 
The only observed complete baseline variable available that was informative of missingness 
in the example dataset, as described above, was age. In Stata, while the data was still in 
long format (multiple observations for each individual in the one column) the data was 
declared as long (mi set mlong), EQ-5D utility scores were declared as the variable to be 
imputed (mi register impute utility score variable), and 30 imputed datasets 
were created using regression analysis and age as an informative observed variable (mi 
impute regress utility score age, add(30)). The data was then reshaped into 
wide, using Rubin’s rule to combine information on each individual, using the “mi reshape” 
command in Stata and further analyses carried out using “mi estimate”. A regression 
analysis run on the imputed data estimated that the mean undiscounted and unadjusted 
QALYs for the control group were1.36 (95% CI 1.25 to 1.47) with the treatment group having 
0.02 QALYs less on average (95% CI -.17 to 0.127). Adjusting for baseline differences in 
utility scores the treatment group had a QALY increase of 0.02 (95% CI -0.089 to 0.129). 
9. Probability distribution 
The examples above do not address the distribution of utility data. Utility scores derived from 
the EQ-5D have a number of distribution issues in that, in addition to having the qualities of a 
maximum value of 1 and minimum value of -0.594, EQ-5D utility scores tend to be positively 
skewed with an identifiable ceiling effect2. Figure 2 is the frequency distribution of the EQ-5D 
utility data at baseline from the example dataset. It is clear from the graph that EQ-5D utility 
scores in this example are not normally distributed. The most common way of addressing 
this in cost-utility analysis is to use non-parametric tests of significance, with the 
recommended method being bootstrapping [27] where N samples of n individuals are taken 
from the original dataset, and then replaced. The process is then repeated a large number of 
times (upwards of 1,000), and for each of these samples the mean of the sample is 
calculated. Further statistics can then be run on these results. Additionally, if these means 
are then stored in memory, this has the added advantage of alongside bootstrapped cost 
data cost-effectiveness planes and cost-effectiveness acceptability curves can be created 
that allow for reporting the percentage of times that the mean of samples for a  given option 
are cost-effective for a willingness to pay for a QALY. Other methods that can take into 
                                                          
2
 Note that some issues with the ceiling effect seen in the EQ-5D have been overcome by the development of a 
5 level version of the questionnaire [37] 
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account the distribution of the data and some of the other issues discussed above are more 
complex regression techniques and seemingly unrelated equations which can also be used 
for hypothesis testing of cost and utility data but are beyond the scope of this article [36]. 
10. Conclusion 
Utility scores and the calculation of QALYs present a number of statistical analysis 
challenges, some of which are due to the nature of clinical trials, such as missing data. This 
paper has demonstrated that the methods used are important as they can impact on the 
direction or magnitude of the results, although in this instance not necessarily the 
conclusions. Use of standardised methods is recommended so as to maintain the original 
intended purpose of utilities and QALYs – comparison across disease areas and different 
programmes of work. If this is not possible though analysts need to ensure that they are 
transparent about their methods and any assumptions made regarding the above areas so 
that decision makers and others are able to make informed decisions about the 
effectiveness of a new technology and whether to implement or to conduct further research.  
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Figure 1: Mean utility scores for treatment and control groups over 2 years (24 
months) 
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Figure 2: Frequency distribution of EQ-5D utility scores at baseline 
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Table 1: Utility scores and QALYs by treatment group 
 Mean (SD) Utility Scores QALYS  Discounted 
Follow up 
point 
Control Treatment Control Treatment Control  Treatment 
Baseline 0.675 (0.28) 0.637 (0.3)     
6 months 0.631 (0.33) 0.605 (0.3) 0.327 0.31 0.327 0.31 
12 months 0.70 (0.25) 0.644 (0.29) 0.333 0.312 0.333 0.312 
24 months 0.711 (0.28) 0.805 (0.28) 0.71 0.724 0.682 0.70 
Total  0.679 (0.28) 0.668 (0.30) 1.37 1.346 1.342 1.322 
SD= standard deviation 
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Table 2: Percentage of individuals missing EQ-5D questionnaires or item responses 
 
  
Control Treatment 
Total – n 
 
67 85 
Baseline n (%) Complete  66 (99%) 83 (98%) 
 
Missing 1 item on EQ-5D  1 (1%) 2 (2%) 
 
Missing EQ-5D 0 0 
6 months n (%) Complete  62 (92%) 82 (96%) 
 
Missing 1 item on EQ-5D 5 (8%) 2 (2%) 
 
Missing EQ-5D 0 1 (1%) 
12 months n (%) Complete  60 (90%) 72 (85%) 
 
Missing 1 item on EQ-5D 0 0 
 
Missing EQ-5D 7 (10%) 13 (15%) 
24 months n (%) Complete  57 (85%) 71 (83%) 
 
Missing 1 item on EQ-5D  4 (6%) 9 (11%) 
 
Missing EQ-5D 6 (9%) 5 (6%) 
Complete across all time points 47 (70%) 60 (71%) 
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Table 3: Total QALYs over 24 months reported by method of analysis.  
 
Undiscounted 
 
Discounted 
 
Control Treatment Control Treatment 
Available Case  
   Group Mean 1.37 1.35 1.34 1.32 
Complete Case     
Group Mean  1.47 (1.36-1.57) 1.39 (1.27-1.51) 1.44 (1.34-1.54) 1.37 (1.25- 1.48) 
Individual level 1.47 (1.36-1.57) 1.39 (1.27-1.51) 1.44 (1.34-1.54) 1.37 (1.25- 1.48) 
Adjusting for baseline 
utilities 
1.35 (1.28-1.43) 1.38 (1.32-1.45) 1.33 (1.26 -1.40) 1.36 (1.3-1.42) 
Multi-level model 1.55 (1.47-1.62) 1.54 (1.44-1.56) 1.52 (1.44-1.60) 1.51 (1.42-1.63) 
Missing data     
Last utility score 
carried forward 
1.35 (1.22-1.46) 1.35 (1.25-1.46) 1.33 (1.21-1.44) 1.33 (1.22-1.43) 
Last utility score 
carried forward 
(adjusted)* 
1.32 (1.24-1.40) 1.37 (1.31-1.44) 1.30 (1.22-1.37) 1.35 (1.28-1.42) 
Last item response 
carried forward 
1.34 (1.23-1.46) 1.35 (1.25-1.46) 1.32 (1.20-1.44) 1.33 (1.22-1.44) 
Last item response 
carried forward 
(adjusted)* 
1.32 (1.24-1.39) 1.38 (1.31-1.44) 1.30 (1.22-1.37) 1.35 (1.28-1.42) 
Multiple imputation 
(unadjusted)* 
1.36 (1.25-1.47) 1.33 (1.24 –1.44) 1.33 (1.23-1.44) 1.32 (1.22-1.41) 
Multiple imputation 
(adjusted)* 
1.24 (1.15-1.33) 1.26 (1.19 –1.33) 1.22 (1.13 –1.30) 1.24 (1.16 –1.31) 
 
*Adjusted: values adjusted for baseline utilities 
